NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03221426,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),https://clinicaltrials.gov/study/NCT03221426,,ACTIVE_NOT_RECRUITING,"The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

The primary study hypotheses are that:

* Neoadjuvant and adjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab is superior to neoadjuvant and adjuvant placebo plus chemotherapy, followed by adjuvant placebo in terms of Event-free Survival (EFS) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), and
* Neoadjuvant pembrolizumab plus chemotherapy is superior to neoadjuvant placebo plus chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.

With Amendment 10, upon study completion, participants will be discontinued and may be enrolled in an extension study.",YES,Gastric Cancer|Gastroesophageal Junction Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Placebo|DRUG: Cisplatin|DRUG: Capecitabine|DRUG: 5-fluorouracil|DRUG: Docetaxel|DRUG: Oxaliplatin|DRUG: Leucovorin,"Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms, EFS is based on RECIST 1.1 as assessed by the investigator and is defined as the time from randomization to the first of the following events: radiographic disease progression per RECIST 1.1; local or distant recurrence as assessed by computer tomography (CT) scan or biopsy if indicated (for participants who are disease free after surgery); clinical progression as evidenced by peritoneal carcinomatosis confirmed by preoperative laparoscopy or laparotomy (for participants who are confirmed to be free of peritoneal involvement by laparoscopy at screening); or death due to any cause. A second primary malignancy, or radiographic progressive disease (PD) during the neoadjuvant phase that does not preclude successful surgery (i.e., disease free after surgery), are not considered EFS events., Up to approximately 75 months|Pathological Complete Response (pathCR) Rate - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms, PathCR rate is defined as the percentage of participants having a pathCR based on central review. pathCR is defined as no invasive disease within an entirely submitted and evaluated gross lesion, and histologically negative nodes. The percentage of participants having pathCR is presented for the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms., Up to approximately 9 weeks following completion of neoadjuvant treatment (up to Study Week 18)|Overall Survival (OS) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms, OS is defined as the time from randomization to death due to any cause. OS is presented for the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms., Up to approximately 75 months|Number of Participants Who Experience One or More Adverse Events (AEs) - Pembrolizumab+FLOT and Placebo+FLOT Cohorts, An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE is presented for the Pembrolizumab+FLOT and Placebo+FLOT Cohorts., Up to approximately 70 months|Number of Participants Who Discontinue Study Treatment Due to an AE - Pembrolizumab+FLOT and Placebo+FLOT Cohorts, An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE is presented for the Pembrolizumab+FLOT and Placebo+FLOT Cohorts., Up to approximately 17 months","Number of Participants Who Experience One or More Adverse Events (AEs) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts, An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented for the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms separately and in combination with the Pembrolizumab+FLOT and Placebo+FLOT Cohorts., Up to approximately 75 months|Number of Participants Who Discontinue Study Treatment Due to an AE - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts, An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms separately and in combination with the Pembrolizumab+FLOT and Placebo+FLOT Cohorts., Up to approximately 18 months|Disease-free Survival (DFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms, DFS is defined as the time from post-surgery baseline scan until the first occurrence of local or distant recurrence or death from any cause and is based on RECIST 1.1 as assessed by the investigator., Up to approximately 75 months|Overall Survival (OS) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts, OS is defined as the time from randomization to death due to any cause. OS is presented for the Pembrolizumab+XP/FP and Placebo+XP/FP treatment arms in combination with the Pembrolizumab+FLOT and Placebo+FLOT Cohorts., Up to approximately 75 months|Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts, EFS is based on RECIST 1.1 as assessed by the investigator and is defined as the time from randomization to the first of the following events: radiographic disease progression per RECIST 1.1; local or distant recurrence as assessed by CT scan or biopsy if indicated (for participants who are disease free after surgery); clinical progression as evidenced by peritoneal carcinomatosis confirmed by preoperative laparoscopy or laparotomy (for participants who are confirmed to be free of peritoneal involvement by laparoscopy at screening); or death due to any cause. A second primary malignancy, or radiographic progressive disease (PD) during the neoadjuvant phase that does not preclude successful surgery (i.e., disease free after surgery), are not considered EFS events., Up to approximately 75 months",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,1007,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",3475-585|MK-3475-585|173786|KEYNOTE-585|PHRR200226-002534|2016-004408-76,2017-10-09,2024-02-16,2025-04-23,2017-07-18,2025-02-20,2025-02-20,"City of Hope ( Site 0005), Duarte, California, 91010, United States|Yale Cancer Center ( Site 0016), New Haven, Connecticut, 06520, United States|Georgetown University ( Site 0015), Washington, District of Columbia, 20007, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0018), Chicago, Illinois, 60611, United States|The University of Chicago Medical Center ( Site 0004), Chicago, Illinois, 60637, United States|Roswell Park Cancer Institute ( Site 0001), Buffalo, New York, 14263, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0019), New York, New York, 10016, United States|Memorial Sloan Kettering ( Site 0024), New York, New York, 10065, United States|Weill Cornell Medical Center ( Site 0023), New York, New York, 10065, United States|University of Rochester ( Site 0011), Rochester, New York, 14642, United States|Fox Chase Cancer Center ( Site 0006), Philadelphia, Pennsylvania, 19111, United States|Temple University Hospital ( Site 0026), Philadelphia, Pennsylvania, 19140, United States|University of Utah, Huntsman Cancer Institute ( Site 0012), Salt Lake City, Utah, 84112, United States|Virginia Cancer Specialists, PC ( Site 0010), Fairfax, Virginia, 22031, United States|Institut Jules Bordet ( Site 0480), Brussels, Bruxelles-Capitale, Region De, 1000, Belgium|Hopital Erasme ULB ( Site 0484), Brussels, Bruxelles-Capitale, Region De, 1070, Belgium|UCL Saint Luc ( Site 0479), Bruxelles, Bruxelles-Capitale, Region De, 1200, Belgium|Grand Hopital de Charleroi ( Site 0478), Charleroi, Hainaut, 6000, Belgium|CHU de Liege ( Site 0482), Li√®ge, Liege, 4000, Belgium|CHU UCL Namur Site de Godinne ( Site 0485), Yvoir, Namur, 5530, Belgium|UZ Gent ( Site 0486), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 0483), Leuven, Vlaams-Brabant, 3000, Belgium|AZ Groeninge ( Site 0481), Kortrijk, West-Vlaanderen, 8500, Belgium|Instituto do Cancer do Ceara ( Site 0311), Fortaleza, Ceara, 60430-230, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0308), Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|CEPON - Centro de Pesquisas Oncologicas ( Site 0302), Florianopolis, Santa Catarina, 88034-000, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0301), Barretos, Sao Paulo, 14784-400, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 0304), Sao Jose Rio Preto, Sao Paulo, 15090-000, Brazil|Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0307), Rio de Janeiro, 20230-130, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0305), Sao Paulo, 01246-000, Brazil|Hospital Israelita Albert Einstein ( Site 0309), Sao Paulo, 05652-900, Brazil|Cross Cancer Institute ( Site 0033), Edmonton, Alberta, T6G 1Z2, Canada|Moncton Hospital - Horizon Health Network ( Site 0038), Moncton, New Brunswick, E1C 6Z8, Canada|Sunnybrook Research Institute ( Site 0032), Toronto, Ontario, M4N 3M5, Canada|CISSS de la Monteregie-Centre ( Site 0039), Greenfield Park, Quebec, J4V 2H1, Canada|CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0040), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0034), Montreal, Quebec, H3T 1E2, Canada|CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0035), Sherbrooke, Quebec, J1H 5N4, Canada|CHU de Quebec - Hotel-Dieu de Quebec ( Site 0042), Quebec, G1R 2J6, Canada|Instituto Clinico del Sur. ICOS ( Site 0290), Temuco, Araucania, 4810469, Chile|Hospital Regional Rancagua Libertador Bernardo O Higgins ( Site 0299), Rancagua, Lbtdr Gen Bernardo O Higgins, 2820000, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0286), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile ( Site 0285), Santiago, Region M. De Santiago, 8330032, Chile|Hospital Clinico Universidad de Chile ( Site 0287), Santiago, Region M. De Santiago, 8380456, Chile|Beijing Cancer Hospital ( Site 0221), Beijing, Beijing, 100142, China|Zhejiang Cancer Hospital ( Site 0231), Hangzhou, Zhejiang, 310022, China|Sir Run Run Shaw Hospital ( Site 0233), Hangzhou, Zhejiang, 430030, China|SA Pohja-Eesti Regionaalhaigla ( Site 0526), Tallinn, Harjumaa, 13419, Estonia|Hopital Prive Jean Mermoz ( Site 0462), Lyon, Auvergne, 69008, France|Institut Paoli Calmettes ( Site 0472), Marseille, Bouches-du-Rhone, 13009, France|CHU Reims - Hopital Robert Debre ( Site 0465), Reims, Champagne-Ardenne, 51092, France|CHU Brest - Institut de Cancerologie et d Hematologie ( Site 0474), Brest, Finistere, 29200, France|CHU Toulouse - Hopital Rangueil ( Site 0470), Toulouse, Haute-Garonne, 31059, France|Institut du Cancer de Montpellier ( Site 0473), Montpellier, Herault, 34298, France|Centre Eugene Marquis ( Site 0466), Rennes, Ille-et-Vilaine, 35042, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0469), Saint Herblain, Loire-Atlantique, 44805, France|CHRU Lille - Hopital Claude Huriez ( Site 0461), Lille, Nord, 59037, France|CHU Poitiers - Pole Regional de Cancerologie ( Site 0467), Poitiers, Vienne, 86021, France|CHU Hopital Saint Antoine ( Site 0471), Paris, 75012, France|Institut Mutualiste Montsouris ( Site 0463), Paris, 75014, France|Klinikum Esslingen GmbH ( Site 0453), Esslingen, Baden-Wurttemberg, 73730, Germany|Universitaetsklinikum Freiburg ( Site 0450), Freiburg, Baden-Wurttemberg, 79106, Germany|Klinikum der Universitaet in Muenchen ( Site 0446), Muenchen, Bayern, 81377, Germany|Medizinische Hochschule Hannover ( Site 0449), Hannover, Niedersachsen, 30625, Germany|Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 0445), Essen, Nordrhein-Westfalen, 45136, Germany|Medizinische klinilk und Poliklinik Johannes Gutenberg Univ ( Site 0455), Mainz, Rheinland-Pfalz, 55131, Germany|Universitaetsklinikum Carl Gustav Carus der TU Dresden ( Site 0448), Dresden, Sachsen, 01307, Germany|Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 0454), Hamburg, 20249, Germany|Integra Cancer Institute ( Site 0262), Guatemala, 01010, Guatemala|Grupo Medico Angeles ( Site 0261), Guatemala, 01015, Guatemala|Centro Medico Integral De Cancerolog√≠a (CEMIC) ( Site 0260), Quetzaltenango, 09002, Guatemala|Soroka University M.C ( Site 0385), Beer Sheva, HaDarom, 8410101, Israel|Meir medical center ( Site 0386), Kfar Saba, HaMerkaz, 4428164, Israel|Sourasky Medical Center. ( Site 0382), Tel-Aviv, Tell Abib, 6423906, Israel|Rambam Health Care Campus ( Site 0381), Haifa, 31096, Israel|Hadassah Medical Center. Ein Kerem ( Site 0383), Jerusalem, 9112001, Israel|Rabin-Medical Center ( Site 0384), Petah Tikva, 4941492, Israel|Sheba Medical center ( Site 0387), Ramat Gan, 5265601, Israel|IRCCS Istituto Oncologico Veneto ( Site 0431), Padova, Abruzzo, 35128, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0430), Milano, Lombardia, 20133, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0432), Rozzano, Milano, 20089, Italy|IRCCS Policlinico San Donato ( Site 0433), San Donato Milanese, Milano, 20097, Italy|Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0429), Modena, 41125, Italy|Seconda Universita Napoli ( Site 0436), Napoli, 80131, Italy|A.O.U. Santa Maria della Misericordia di Udine ( Site 0434), Udine, 33100, Italy|Aichi Cancer Center Hospital ( Site 0165), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 0178), Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center ( Site 0186), Matsuyama, Ehime, 791-0280, Japan|Hokkaido University Hospital ( Site 0160), Sapporo, Hokkaido, 060-8648, Japan|Hyogo Cancer Center ( Site 0182), Akashi, Hyogo, 673-8558, Japan|Kobe University Hospital ( Site 0188), Kobe, Hyogo, 650-0017, Japan|Kobe City Medical Center General Hospital ( Site 0181), Kobe, Hyogo, 650-0047, Japan|Ibaraki Prefectural Central Hospital ( Site 0177), Kasama, Ibaraki, 309-1793, Japan|Iwate Medical University Hospital ( Site 0184), Shiwa-gun, Iwate, 028-3695, Japan|St. Marianna University School of Medicine Hospital ( Site 0187), Kawasaki, Kanagawa, 216-8511, Japan|Kanagawa Cancer Center ( Site 0167), Yokohama, Kanagawa, 241-8515, Japan|Kansai Medical University Hospital ( Site 0190), Hirakata, Osaka, 573-1191, Japan|Osaka University Hospital ( Site 0162), Suita, Osaka, 565-0871, Japan|Osaka Medical College Hospital ( Site 0168), Takatsuki, Osaka, 569-8686, Japan|Saitama Cancer Center ( Site 0170), Kitaadachi-gun, Saitama, 362-0806, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 0176), Sunto-gun, Shizuoka, 411-8777, Japan|Chiba Cancer Center ( Site 0180), Chiba, 260-8717, Japan|National Hospital Organization Kyushu Cancer Center ( Site 0172), Fukuoka, 811-1395, Japan|Kyushu University Hospital ( Site 0173), Fukuoka, 812-8582, Japan|Gifu University Hospital ( Site 0166), Gifu, 501-1194, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 0171), Hiroshima, 730-8518, Japan|Kochi Health Sciences Center ( Site 0189), Kochi, 781-8555, Japan|Kumamoto University Hospital ( Site 0164), Kumamoto, 860-8556, Japan|Niigata Cancer Center Hospital ( Site 0169), Niigata, 951-8566, Japan|Osaka International Cancer Institute ( Site 0161), Osaka, 541-8567, Japan|Osaka General Medical Center ( Site 0159), Osaka, 558-8558, Japan|National Cancer Center Hospital ( Site 0179), Tokyo, 104-0045, Japan|Tokyo Metropolitan Komagome Hospital ( Site 0183), Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR ( Site 0185), Tokyo, 135-8550, Japan|Toyama Prefectural Central Hospital ( Site 0163), Toyama, 930-8550, Japan|Chonnam National University Hwasun Hospital ( Site 0083), Hwasun Gun, Jeonranamdo, 58128, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0085), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of|Kyungpook National University Chilgok Hospital ( Site 0089), Daegu, Taegu-Kwangyokshi, 41404, Korea, Republic of|Gachon University Gil Medical Center ( Site 0087), Incheon, 21565, Korea, Republic of|Korea University Anam Hospital ( Site 0084), Seoul, 02841, Korea, Republic of|Seoul National University Hospital -SNUH- ( Site 0080), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0081), Seoul, 03722, Korea, Republic of|Asan Medical Center ( Site 0082), Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital ( Site 0088), Seoul, 06273, Korea, Republic of|SMG-SNU BORAMAE Medical Center ( Site 0086), Seoul, 07061, Korea, Republic of|Riga East Clinical University Hospital ( Site 0550), Riga, 1079, Latvia|LSMUL Kauno Klinikos ( Site 0570), Kaunas, 50161, Lithuania|Nacionalinis Vezio Institutas ( Site 0569), Vilnius, 08406, Lithuania|Vilniaus Universiteto Ligonine Santaros Klinikos ( Site 0568), Vilnius, 08460, Lithuania|Hospital Kuala Lumpur ( Site 0146), Kuala Lumpur, 50586, Malaysia|University Malaya Medical Centre ( Site 0143), Kuala Lumpur, 59100, Malaysia|St. Luke s Medical Center ( Site 0622), Quezon City, National Capital Region, 1102, Philippines|Wojewodzki Szpital Specjalistyczny we Wroclawiu ( Site 0358), Wroclaw, Dolnoslaskie, 51-124, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 0351), Lublin, Lubelskie, 20-080, Poland|Szpital Uniwersytecki w Krakowie ( Site 0352), Krakow, Malopolskie, 31-501, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0349), Warszawa, Mazowieckie, 02-034, Poland|Mazowiecki Szpital Onkologiczny ( Site 0363), Wieliszew, Mazowieckie, 05-135, Poland|Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0353), Koscierzyna, Pomorskie, 83-400, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 0354), Bielsko-Biala, Slaskie, 43-300, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0361), Gliwice, Slaskie, 44-101, Poland|SPZOZ WSS nr 3 w Rybniku ( Site 0357), Rybnik, Slaskie, 44-200, Poland|Kaluga Regional Clinical Oncology Center ( Site 0345), Kaluga, Kaluzskaja Oblast, 248007, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 0496), Saint Petersburg, Leningradskaya Oblast, 194291, Russian Federation|National Medical and Surgical Center n.a. N.I.Pirogov ( Site 0338), Moscow, Moskva, 105203, Russian Federation|Blokhin National Medical Oncology ( Site 0494), Moscow, Moskva, 115478, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0344), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation|Leningrad Regional Oncology Center ( Site 0335), Saint-Petersburg, Sankt-Peterburg, 188663, Russian Federation|City clinical oncological dispensary ( Site 0336), Sankt-Petersburg, Sankt-Peterburg, 198255, Russian Federation|Tomsk Scientific Research Institute of Oncology ( Site 0337), Tomsk, Tomskaya Oblast, 634028, Russian Federation|National University Hospital ( Site 0095), Singapore, Central Singapore, 119074, Singapore|National Cancer Centre Singapore ( Site 0097), Singapore, Central Singapore, 169610, Singapore|Oncocare Cancer Centre ( Site 0096), Singapore, Central Singapore, 258499, Singapore|Taipei Medical University Shuang Ho Hospital ( Site 0068), New Taipei, 235, Taiwan|National Cheng Kung University Hospital ( Site 0067), Tainan, 704, Taiwan|National Taiwan University Hospital ( Site 0063), Taipei, 10002, Taiwan|Mackay Memorial Hospital ( Site 0065), Taipei, 104, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 0066), Taipei, 11259, Taiwan|Chang Gung Medical Foundation. Linkou ( Site 0064), Taoyuan, 333, Taiwan|City Clinical Hosp.4 of DCC ( Site 0325), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 0589), Kryviy Rih, Dnipropetrovska Oblast, 50048, Ukraine|Ivano-Frankivsk Regional Oncology Clinical Dispensary ( Site 0321), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76018, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 0591), Kharkiv, Kharkivska Oblast, 61070, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 0319), Kyiv, Kyivska Oblast, 03022, Ukraine|Kyiv City Clinical Oncology Center ( Site 0590), Kyiv, Kyivska Oblast, 03115, Ukraine|University Hospitals Bristol NHS Foundation Trust ( Site 0407), Bristol, Bristol, City Of, BS2 8ED, United Kingdom|Ninewells Hospital and Medical School ( Site 0406), Dundee, Dundee City, DD1 9SY, United Kingdom|Royal Free London NHS Foundation Trust ( Site 0403), London, London, City Of, NW3 2QG, United Kingdom|The Royal Marsden Foundation Trust ( Site 0405), London, London, City Of, SW3 6JJ, United Kingdom|Imperial College Healthcare NHS Trust ( Site 0402), London, London, City Of, W2 1NY, United Kingdom|Royal Marsden NHS Foundation Trust ( Site 0400), Sutton, Surrey, SM2 5PT, United Kingdom|The Christie NHS Foundation Trust ( Site 0397), Manchester, M20 4BX, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/26/NCT03221426/Prot_SAP_000.pdf"
